此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PF-06741086 在患有严重血友病 A 或中重度至重度血友病 B 的成人和青少年参与者中的疗效和安全性研究

2026年7月23日 更新者:Pfizer

青少年和成人严重(凝血因子活性)的开放标签研究

与目前治疗血友病 A 或 B 的方法相比,使用 PF-06741086 治疗有望证明临床相关优势和/或对患者护理的重大贡献,因为它的作用不同于因子替代产品,并且会在存在抑制剂的情况下起作用. 每周一次 (QW) 皮下 (SC) 给药的潜力在没有可靠血管通路的情况下提供了治疗选择,增加了便利性并可能实现更好的依从性。 结合起来,这些品质应该会导致出血事件的减少。

研究概览

地位

完全的

研究类型

介入性

注册 (实际的)

188

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100045
        • Beijing Children's Hospital, Capital Medical University
    • Guangdong
      • Guangzhou、Guangdong、中国、510515
        • Nanfang Hospital, Southern Medical University
    • Guizhou
      • Guiyang、Guizhou、中国、550004
        • The Affiliated Hospital of Guizhou Medical University
    • Jiangxi
      • Nanchang、Jiangxi、中国、306113
        • Jiangxi Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300020
        • Institute of Hematology, Chinese Academy of Medical Sciences
      • Samara、俄罗斯、443079
        • FGBOU VO "Samara State Medical University" of MoH of Russia
      • Sofia、保加利亚、1756
        • National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
      • Stara Zagora、保加利亚、6003
        • UMHAT "Prof.Dr. Stoyan Kirkovich"
      • Zagreb、克罗地亚、10000
        • Klinicki bolnicki centar Zagreb
    • Ontario
      • Hamilton、Ontario、加拿大、L8S 4K1
        • McMaster University
      • Hamilton、Ontario、加拿大、L8S 4K1
        • McMaster Children's Hospital
      • Hamilton、Ontario、加拿大、L8N 3Z5
        • McMaster University Medical Centre - Hamilton Health Sciences
      • Toronto、Ontario、加拿大、M5G 1X8
        • The Hospital for Sick Children
    • Gauteng
      • Johannesburg、Gauteng、南非、2193
        • Charlotte Maxeke Johannesburg Academic Hospital
    • Gujarat
      • Surat、Gujarat、印度、395002
        • Nirmal Hospital Pvt, Ltd
    • Maharashtra
      • Pune、Maharashtra、印度、411004
        • Sahyadri Super Speciality Hospital
      • Pune、Maharashtra、印度、411004
        • Sahyadri Clinical Research And Development Center
    • Tamil Nadu
      • Vellore、Tamil Nadu、印度、632004
        • Christian Medical College
      • Taichung、台湾、40705
        • Taichung Veterans General Hospital
    • Changhua County
      • Changhua、Changhua County、台湾、500
        • Changhua Christian Hospital
      • Adana、土耳其(türkiye)、01130
        • Acibadem Adana Hospital
      • Ankara、土耳其(türkiye)、06230
        • Hacettepe University Medical Faculty
      • Ankara、土耳其(türkiye)、06500
        • Gazi University Health Research and Practice Center Gazi Hospital
      • Antalya、土耳其(türkiye)、07060
        • Akdeniz University Medical Faculty
      • Gaziantep、土耳其(türkiye)、27310
        • Gaziantep University Sahinbey Research and Training Hospital
      • Istanbul、土耳其(türkiye)、34093
        • Istanbul University Oncology Institute
      • Izmir、土耳其(türkiye)、35040
        • Ege University Medical Faculty
      • Izmir、土耳其(türkiye)、35210
        • Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
      • Kayseri、土耳其(türkiye)、38039
        • Erciyes University Medical Faculty
      • Samsun、土耳其(türkiye)、55280
        • Ondokuz Mayıs University Medical Faculty
      • Trabzon、土耳其(türkiye)、61080
        • Karadeniz Technical University Medical Faculty
      • Belgrade、塞尔维亚、11000
        • Clinical Center of Serbia
      • Belgrade、塞尔维亚、11000
        • Institute for Mother and Child healthcare "Dr Vukan Cupic"
      • Kragujevac、塞尔维亚、34000
        • Clinical Center Kragujevac
      • Niš、塞尔维亚、18000
        • Clinical Center Niš
    • Nuevo León
      • Monterrey、Nuevo León、墨西哥、64460
        • Hospital Universitario "Dr Jose Eleuterio Gonzalez"
    • Yucatán
      • Mérida、Yucatán、墨西哥、97130
        • Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
      • Perugia、意大利、06156
        • Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
    • Milan
      • Milan、Milan、意大利、20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    • RM
      • Roma、RM、意大利、00161
        • Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
      • Hiroshima、日本、734-8551
        • Hiroshima University Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、466-8560
        • Nagoya University Hospital - Transfusion Medicine
    • Hokkaido
      • Sapporo、Hokkaido、日本、004-0041
        • Sapporo Tokushukai Hospital
    • Saitama
      • Iruma-gun、Saitama、日本、350-0495
        • Saitama Medical University Hospital
      • Jeddah、沙特阿拉伯、21589
        • King AbdulAziz University Hospital
      • Riyadh、沙特阿拉伯
        • King Faisal Specialist Hospital & Research Center
      • Paris、法国、75015
        • Hôpital Necker Enfants malades
    • Florida
      • Tampa、Florida、美国、33612
        • USF Health Morsani Center for Advanced Healthcare
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa
    • New York
      • New Hyde Park、New York、美国、11040
        • Northwell Health HTC
    • Washington
      • Seattle、Washington、美国、98101
        • Washington Institute for Coagulation
      • A Coruña、西班牙、15006
        • Hospital Universitario A Coruna
      • Barcelona、西班牙、08035
        • Hospital Universitario Vall d´Hebron
      • Madrid、西班牙、28046
        • Hospital Universitario La Paz
      • Salamanca、西班牙、37007
        • Hospital Universitario De Salamanca
      • Zaragoza、西班牙、50009
        • Hospital Universitario Miguel Servet
      • Muscat、阿曼、123
        • Sultan Qaboos University Hospital
      • Daegu、韩国、41944
        • Kyungpook National University Hospital
      • Seoul、韩国、03722
        • Severance Hospital, Yonsei University Health System
      • Seoul、韩国、05278
        • Kyung Hee University Hospital at Gangdong
      • Hong Kong、香港
        • Queen Mary Hospital
      • Hong Kong、香港
        • Prince of Wales Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 74年 (孩子、成人、年长者)

接受健康志愿者

不

描述

纳入标准

  • 诊断为重度血友病 A 或中重度至重度血友病 B 且筛选时体重至少为 35 公斤的参与者。
  • 参与者或合法授权代表,或参与者的护理人员能够签署知情同意书(或轻微同意,如适用)。

加入非抑制剂队列的参与者还必须满足以下条件:

  • 没有可检测或记录的抑制剂历史
  • 接受 FVIII/FIX 常规预防的参与者在入组前 6 个月内已证明至少 80% 遵守预定的预防方案,并愿意在观察阶段继续接受 FVIII/FIX 替代的常规预防治疗。
  • 在入组前 6 个月内发生 ≥ 6 次急性出血事件(自发性或外伤性)且需要输注凝血因子并愿意在观察阶段继续接受按需治疗的按需治疗方案的参与者。

加入抑制剂队列的参与者还必须满足以下标准:

  • 当前高滴度抑制剂 (≥5 BU/mL) 或当前低滴度抑制剂 (<5 BU/mL) 对 FVIII 或 FIX 替代品难治且 FVIII 或 FIX 恢复 <60% 的登记前 6 个月内预期的记录观察阶段
  • 血友病 A 参与者按需治疗方案有 ≥ 6 次出血事件或血友病 B 参与者有 ≥ 4 次出血事件(自发性或外伤性)在进入观察阶段前 6 个月内需要旁路因子治疗并愿意继续接受-在观察阶段需要治疗。
  • 在接受因子替代疗法时记录到抑制物但在筛选时不符合先前项目符号中描述的定量抑制物标准的参与者(例如,参与者之前记录到高滴度抑制物(≥5 BU/mL)和其条件排除了 FVIII 或 FIX 替代物的重新挑战)可以在辉瑞医疗监测员事先同意的情况下根据具体情况考虑资格
  • 符合上述出血标准并正在进行常规预防(定义为通过静脉注射旁路因子治疗以预防出血)并且在入组前 6 个月内至少 80% 遵守预定预防方案的参与者,可能是在辉瑞医疗监督员的讨论和同意下,逐案考虑资格。

排除标准

  • 冠状动脉疾病、静脉或动脉血栓形成或缺血性疾病的既往或当前治疗和/或病史
  • 在计划的研究期间已知的计划手术程序。
  • 除血友病 A 或 B 以外的已知止血缺陷。
  • 肾功能或肝功能异常
  • 目前不稳定的肝脏或胆道疾病
  • 血液学参数异常
  • 其他急性或慢性医学或精神疾病或实验室异常,可能会增加与研究参与或研究产品给药相关的风险,或可能会干扰研究结果的解释,并且根据研究者的判断,
  • 当前使用旁路剂或非凝血非因子替代疗法进行常规预防,或之前使用基因治疗产品治疗血友病(使用旁路剂进行预防性治疗或之前使用非因子产品治疗的参与者可能逐案考虑)。
  • 免疫调节药物的常规联合治疗

    -在观察阶段或积极治疗阶段持续或计划使用免疫耐受诱导,或在积极治疗阶段开始研究干预治疗后随时使用 FVIII 或 FIX 替代进行预防

  • 在参与研究 B7841002 和 B7841003 期间曾接触过 PF 06741086。
  • 在进入研究前和/或参与研究期间,在 30 天内(或根据当地要求确定)或 5 个半衰期内参与涉及研究药物或研究疫苗的其他研究。
  • 如果人类免疫缺陷病毒 (HIV) 阳性,CD4 细胞计数≤200/uL
  • 筛选 ECG,表明可能影响参与者安全或研究结果解释的临床相关异常。
  • 对仓鼠蛋白或研究干预的其他成分有超敏反应或过敏反应的个体。
  • 直接参与研究开展的研究者现场工作人员及其家庭成员、研究者在其他方面监督的研究中心工作人员,或者直接参与研究开展的辉瑞员工参与者,包括他们的家庭成员。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PF-06741086
在当前血友病治疗方案的 6 个月观察期后,参与者将被分配接受 PF-06741086 治疗。
300 毫克 (mg) 皮下 (sc) 负荷剂量,然后每周一次 (qw) 150 mg sq。 为符合剂量递增标准的参与者规定了 300 mg sc qw。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious AEs and all other AEs.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening. A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
大体时间:During prophylaxis treatment in ATP (12 months)
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response. NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
大体时间:During prophylaxis treatment in ATP (12 months)
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks. Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up. Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between. Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
大体时间:During prophylaxis treatment in ATP (12 months)
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling. ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death. In this outcome measure only categories with non-zero values reported.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Height and weight were also measured and recorded. Clinical significance in physical examinations was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure. Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets. Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium. Clinical significance of laboratory parameters was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
大体时间:During prophylaxis treatment in ATP (12 months)
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating. Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
During prophylaxis treatment in ATP (12 months)

次要结果测量

结果测量
措施说明
大体时间
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days. Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Target joint: a major joint into which repeated bleeds occurred. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
大体时间:OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication). Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed. Total bleeds: Treated bleeds + untreated bleeds. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
大体时间:Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
PGIC-H at Month 6: Inhibitor Cohort
大体时间:Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
大体时间:OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年3月9日

初级完成 (实际的)

2025年4月29日

研究完成 (实际的)

2025年4月29日

研究注册日期

首次提交

2019年5月2日

首先提交符合 QC 标准的

2019年5月2日

首次发布 (实际的)

2019年5月6日

研究记录更新

最后更新发布 (实际的)

2026年8月14日

上次提交的符合 QC 标准的更新

2026年7月23日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

辉瑞将提供对个人去识别参与者数据和相关研究文件(例如 协议、统计分析计划 (SAP)、临床研究报告 (CSR))根据合格研究人员的要求,并遵守某些标准、条件和例外情况。 有关辉瑞数据共享标准和请求访问流程的更多详细信息,请访问:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests。

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅